Skip to main content
SpringerLink
Log in

Is the Dosing and Timing of the Intervention Adequate?

  • Conference paper
Sepsis and Organ Dysfunction

  • 113 Accesses

Abstract

During the last decade, major advances have been made in defining mechanisms of shock and organ injury due to infection. Intact host inflammatory responses are critical to limit and resolve serious infections. However, when these responses are intense they contribute to tissue injury and organ failure. Attempts to suppress inflammatory responses using corticosteroids or mediator-specific antagonists (e.g. tumor necrosis factor (TNF) antibodies) have either not improved survival or have been harmful in septic patients with life-threatening infections [13]. The rationale for the use of anti-inflammatory agents in sepsis seems well founded. The proinflammatory cytokines TNF and IL-1 are detected during infections and when administered to humans or animals result in manifestations of shock. In some animal models, antagonists to TNF or IL-1 protect them from lethal bacterial challenge [4] . However, the inability to translate these observations into clinical use has led to a reassessment of this therapeutic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25:1095–1100

    Article  PubMed  CAS  Google Scholar 

  2. Bone RC, Fisher CJ Jr, Clemmer TP et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658

    Article  PubMed  CAS  Google Scholar 

  3. Fisher CJ Jr, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334:1697–1702

    Article  PubMed  CAS  Google Scholar 

  4. Natanson C, Hoffman WD, Suffredini AF et al (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771–783

    PubMed  CAS  Google Scholar 

  5. Cronin L, Cook DJ, Carlet J et al (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 23:1430–1439

    Article  PubMed  CAS  Google Scholar 

  6. Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis and septic shock: a metaanalysis. Crit Care Med 23:1294–1303

    Article  PubMed  CAS  Google Scholar 

  7. Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26:1927–1931

    Article  PubMed  CAS  Google Scholar 

  8. Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147

    Article  PubMed  CAS  Google Scholar 

  9. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  PubMed  CAS  Google Scholar 

  10. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871

    Article  PubMed  CAS  Google Scholar 

  11. Eichacker PQ (1997) The relevance of animal models in sepsis. In: The Second International Symposium on Infections in the Critically Ill Patient. Feb 14, Barcelona, Spain

    Google Scholar 

  12. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659–665

    Article  Google Scholar 

  13. Abraham E, Wunderink R, Silverman H et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273:934–941

    Article  PubMed  CAS  Google Scholar 

  14. Abraham E, Anzueto A, Gutierrez G et al (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Norasept II Study Group. Lancet 351:929–933

    PubMed  CAS  Google Scholar 

  15. Rolan P (1997) The contribution of clinical pharmacology surrogates and models to drug development — a critical appraisal. Br J Clin Pharmacol 44:219–225

    Article  PubMed  CAS  Google Scholar 

  16. Goldie AS, Fearon KC, Ross JA et al (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 274:172–177

    Article  PubMed  CAS  Google Scholar 

  17. Reinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, doseranging study. Crit Care Med 24:733–742

    Article  PubMed  CAS  Google Scholar 

  18. Abraham E, Glauser MP, Butler T et al (1997) p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 Study Group. JAMA 277:1531–1538

    Article  PubMed  CAS  Google Scholar 

  19. Kay C (1996) Can better measures of cytokine responses be obtained to guide cytokine inhibition? In: Institutes’ CH (ed) Designing Better Drugs and Clinical Trials for Sepsis/SIRS: Reducing Mortality to Patients and Suppliers. Feb 20–21, Washington, DC

    Google Scholar 

  20. Suffredini AF, Reda D, Banks SM et al (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 155:5038–5045

    PubMed  CAS  Google Scholar 

  21. Preas HL, Reda D, Tropea M et al (1996) Effects of recombinant soluble type I IL-1 receptor on human inflammatory responses to endotoxin. Blood 88:2465–2472

    PubMed  CAS  Google Scholar 

  22. Bollaert PE, Charpentier C, Levy B et al (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650

    Article  PubMed  CAS  Google Scholar 

  23. Briegel J, Forst H, Haller M et al (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single center study. Crit Care Med 27:723–732

    Article  PubMed  CAS  Google Scholar 

  24. Chawla K, Kupfer Y, Goldman I, Tessler S (1999) Hydrocortisone reverses refractory septic shock (abstract). Crit Care Med 27[Suppl]:A33

    Article  Google Scholar 

  25. Meduri GU, Kanangat S (1998) Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 26:630–633

    Article  PubMed  CAS  Google Scholar 

  26. Parent C, Natanson C, Cui X et al (1999) Control mortality and exclusion criteria: factors potentially altering the effects of anti-inflammatory therapies in clinical sepsis. Am J Resp Crit Care Med 159:A263

    Google Scholar 

  27. Brandtzaeg P, Osnes L, Ovstebo R et al (1996) Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin10 as a major functional deactivator of human monocytes. J Exp Med 184:51–60

    Article  PubMed  CAS  Google Scholar 

  28. Nylen ES, Whang KT, Snider RH Jr et al (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26:1001–1006

    Article  PubMed  CAS  Google Scholar 

  29. Wang H, Bloom O, Zhang M et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248–251

    Article  PubMed  CAS  Google Scholar 

  30. The Chipping Forecast (1999) Nature Genetics January:1–60

    Google Scholar 

  31. Iyer VR, Eisen MB, Ross DT et al (1999) The transcriptional program in the response of human fibroblasts to serum. Science 283:83–87

    Article  PubMed  CAS  Google Scholar 

  32. Ramsay G (1998) DNA chips: state-of-the art. Nat Biotechnol 16:40–44

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. F. Suffredini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Health Sciences Center, Saint Louis University, St. Louis, USA

    A. E. Baue M.D.

  2. Department of Anaesthesia, Intensive Care and Pain Therapy, Cattinara Hospital, University of Trieste, Trieste, Italy

    G. Berlot M.D.  & A. Gullo M.D.  & 

  3. Department of Intensive Care, Erasme University Hospital, Free University of Brussels, Belgium

    J.-L. Vincent M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Italia

About this paper

Cite this paper

Suffredini, A.F. (2000). Is the Dosing and Timing of the Intervention Adequate?. In: Baue, A.E., Berlot, G., Gullo, A., Vincent, JL. (eds) Sepsis and Organ Dysfunction. Springer, Milano. https://doi.org/10.1007/978-88-470-2284-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2284-3_17

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0096-4

  • Online ISBN: 978-88-470-2284-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation